olaparib,bevacizumab
Merck,roche,AstraZeneca
['solo1']
 i see now that the answer to my question for solo1 was on the slide. only 44.3% in the control arm had desirable crossover. this is just too bad. we must get better in kindergarden 101 basics of trial-design.
75% gynecological oncologist Västerås ????. 25% HTA-unit Camtö Örebro Hospital. Views my own. Words matter. Dislike lifscience like QoL&D engl, swed, germ